iORGANBIO and Mitsui Chemicals team up on AI-driven cell and organoid manufacturing

On November 10, 2026, iORGANBIO announced an investment from Mitsui Chemicals through its 321Catalyst corporate venture fund, alongside a collaboration on human-cell and organoid manufacturing.

The partnership combines iORGANBIO’s platform—which uses AI, single-cell analysis and robotics in a closed-loop laboratory—with Mitsui’s materials expertise, including its InnoCell cell-culture plates.

The companies aim to improve the consistency and quality of cells and organoids, and to make cell types that are difficult to produce more accessible.

They also plan to explore cell- and organoid-based drug testing for efficacy and safety that could complement or serve as alternatives to animal testing. The investment amount was not disclosed.